Marc Gleeson

Azura Ophthalmics Ltd. develops therapies for meibomian gland dysfunction. It offers a portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for meibomian gland dysfunction. The company was founded by Yair Alster in 1980 and is headquartered in Tel Aviv, Israel.

Kedalion Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream platform. The company was founded by Mark Blumenkranz and Ehud Ivri and is headquartered in Menlo Park, CA.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.